On July 25, 2018, Virginia Contract Research Organization Co., Ltd. (VCRO) successfully obtained a permit from the US FDA to carry out a multi-tasked first-in-human trial for a new chemical entity in healthy volunteers. The targeted indication is an orphan pulmonary disorder.
Congratulations! VCRO obtained a clinical-go from the US FDA to launch the clinical development of a NCE for an orphan disease!
On July 25, 2018, Virginia Contract Research Organization Co., Ltd. (VCRO) successfully obtained a permit from the US FDA to carry out a multi-tasked first-in-human trial for a new chemical entity in healthy volunteers. The targeted indication is an orphan pulmonary disorder.